<DOC>
	<DOCNO>NCT00303615</DOCNO>
	<brief_summary>This study patient breast cancer spread tissue organ . The purpose study identify patient may respond favorably certain type hormonal therapy . Researchers study tumor , remove breast surgery . They look presence absence Androgen ( AR ) receptor . These test research purpose . They affect treatment breast cancer . The presence absence Androgen receptor tumor alter therapy offer patient . Recent evidence suggest AR+ tumor likely destroy treat androgen drug . We ask 35 ER-/PR- breast cancer patient Legacy Health System study . All test procedure do outpatient doctor 's office , clinic , hospital . The study drug use trial AndroxyÂ® , synthetic androgen hormone . Androgens show inhibit growth breast cancer cell . Arimidex aromatase inhibitor use conjunction Androxy inhibit vivo production estrogen . It hop combination two drug inhibit growth tumor possibly cause shrink .</brief_summary>
	<brief_title>Androgen Therapy Management Estrogen/Progesterone Receptor Negative ER ( - ) PR ( - ) Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Over 18 year age ER Negative PR Negative Progression disease metastatic set despite taxane chemotherapeutic therapy include Herceptin ( patient Herceptin may continue therapy study ) Maximized chemotherapy metastatic setting patient experience side effect contribute decrease quality life elect defer chemotherapy Evaluable disease either : CT Scan without contrast ( lesion must great 2 mm ) PET Scan , Bone Scan , Plain skeletal film Chest wall skin recurrence ( digital photo capture evaluable disease ) Evaluable symptom ( pain , shortness breath , fatigue , anorexia ) Performance Status 0 , 1 , 2 Bilateral mammogram perform within one year registration Uncontrolled hypercalcemia great 11 Uncontrolled congestive heart failure great 2 NYHA class Central Nervous System metastasis Concomitant steroid use Performance Status great 2 Bilirubin great 5.5</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>ER ( - ) PR ( - )</keyword>
</DOC>